Since both TRPA1 and TRPV1 have received considerable attention as potential therapeutic targets for the treatment of several disorders including chronic pain, inflammation, respiratory diseases, and cancers58–60, further detailed mechanistic analyses of the APP-responsive activations of TRPA1 and TRPV1 channels is anticipated to provide new research insights for developing therapeutic interventions applicable to plasma medicine. This evidence concerns the gene APP and respiratory system disorder.